Original Article
Author Details :
Volume : 9, Issue : 2, Year : 2023
Article Page : 75-81
https://doi.org/10.18231/j.jooo.2023.017
Abstract
The aim of the present study was to investigate the Ki67 expression level and to measure the cell proliferation index (Ki67) in odontogenic benign tumors.
Materials and Methods: This was an analytical cross-sectional study of odontogenic benign tumors. The sampling was non-probabilistic with an exhaustive recruitment including all biopsy or surgical excision specimen of odontogenic benign tumors. Ki67 immunohistochemistry was performed on histological sections of paraffin-fixed tissues of 3µ thickness with the Ki67 (MM1) monoclonal antibody. The studied variables were sociodemographic, clinical and histopathological. The data have been analysed with SPSS 20.0 software.
Result: Ameloblastoma represented 50.9% of cases and cemento-osseous dysplasia 36.4%. Among the 28 ameloblastoma cases, the 15 (53.6%) were plexiform type, the 7 (25%) follicular type and the 6 (21.4%) unicystic type. The percentage of Ki67 labelled cells was less than 1% in 74.6% (n=41) of the tumors and was equal to 5% in 12.7% (n=7) of cases. A Ki67 law labelling was found in 87.3% (n=48) of tumours and a negative labelling in 12.7% (n=7) of cases.
Conclusion: The odontogenic benign tumors had a weak Ki67 expression level and a low epithelial cell proliferation index. The Ki67 could not therefore be used as a predictive biomarker of tumor cell proliferation and the risk of recurrence in odontogenic benign tumors.
Keywords: Odontogenic benign tumor, Cell proliferation index.
How to cite : Diatta M, Gadji M, Dieme M J, Abdou B A, Gassama B C, Kane M, Tamba B, Tine S D, Study of Ki67 in odontogenic benign tumors. J Oral Med Oral Surg Oral Pathol Oral Radiol 2023;9(2):75-81
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Received : 31-03-2022
Accepted : 29-04-2023
Viewed: 786
PDF Downloaded: 222